Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities : compounds modified in the imidazole ring
Journal article, Peer reviewed
Postprint version of article. original can be found at u r l: http://dx.doi.org/10.1016/j.bmc.2010.08.016
MetadataShow full item record
Original versionKhoje, A.D., Kulendrn, A., Charnock, C., Wan, B., Franzblau, S. & Gundersen, L. (2010). Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring. Bioorganic & Medicinal Chemistry, 18 (20), 7274-7282 http://dx.doi.org/10.1016/j.bmc.2010.08.016
Purine analogs modified in the five-membered ring have been synthesized and examined for antibacterial activity against Mycobacterium tuberculosis H37Rv in vitro employing the microplate alamar blue assay (MABA). The 9-deaza analogs were only found to be weak inhibitors, but the 8-aza-, 7-deaza- and 8-aza-7-deazapurine analogs studied displayed excellent antimycobacterial activities, some even substantially better than the parent purine. In the 7-deazapurine series, MIC values between 0.08 and 0.35 lM, values comparable or better than the reference drugs used in the study (MIC rifampicin 0.09 lM, MIC isoniazid 0.28 lM and MIC PA-824 0.44 lM). The five most active compounds were also examined against a panel of drug-resistant Mtb strain, and they all retained their activity. The compounds examined were significantly less active against M. tuberculosis in a state of non-replicating persistence (NRP). MIC in the low-oxygen-recovery assay (LORA)P60 lM. The 7-deazapurines were somewhat more toxic towards mammalian cells, but still the selectivity indexes were excellent. The non-purine analogs exhibit a selective antimycobacterial activity. They were essentially inactive against Staphylococcus aureus and Escherichia coli.